Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
SAVA

SAVA - Cassava Sciences Inc Stock Price, Fair Value and News

$3.10+0.21 (+7.27%)
Market Closed
Max Portfolio Pct.
Check
Valuation
Check

Stock Quality:

GPSDBMFI
Max Portfolio Pct.
Check
Valuation
Check
GPSDBMFI

SAVA Price Action

Last 7 days

-8.5%

Last 30 days

-2.8%

Last 90 days

44.2%

Trailing 12 Months

-7.5%

SAVA RSI Chart

SAVA Valuation

Market Cap

149.8M

Price/Earnings (Trailing)

-1.41

Price/Sales (Trailing)

56.88

EV/EBITDA

-4.16

Price/Free Cashflow

-1.79

SAVA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

SAVA Fundamentals

SAVA Revenue

Revenue (TTM)

2.8M

SAVA Earnings

Earnings (TTM)

-106.0M

Earnings Growth (Yr)

61.32%

Earnings Growth (Qtr)

75.56%

SAVA Profitability

EBT Margin

-509.36%

Return on Equity

-129.99%

Return on Assets

-81.73%

Free Cashflow Yield

-56.01%

SAVA Investor Care

Shares Dilution (1Y)

0.41%

Diluted EPS (TTM)

-2.2

SAVA Alerts

  • 2 major insider buys recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202273.0K374.0K1.2M2.8M
202147.0K33.0K41.0K49.0K
2020308.0K241.0K166.0K112.0K
2019190.5K275.5K340.5K328.0K
201824.0K27.0K38.0K105.5K
201794.0K71.0K54.0K38.0K
201679.0K95.0K103.0K107.0K
201545.0K47.0K51.0K57.0K
201430.9M20.6M10.3M47.0K
20139.9M9.1M8.3M41.1M
201211.2M11.2M11.2M10.9M
201116.8M16.9M16.7M11.5M
2010019.3M18.1M16.8M
200900020.6M
Get all data in R, Python etc through our Historical Stock Data APIs

About Cassava Sciences Inc

SAVA
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The company was incorporated in 1998 and is based in Austin, Texas.
 CEO
 WEBSITEcassavasciences.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES26

Cassava Sciences Inc Frequently Asked Questions

What is the ticker symbol for Cassava Sciences Inc? What does SAVA stand for in stocks?

SAVA is the stock ticker symbol of Cassava Sciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Cassava Sciences Inc (SAVA)?

As of Wed Dec 03 2025, market cap of Cassava Sciences Inc is 149.75 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SAVA stock?

You can check SAVA's fair value in chart for subscribers.

Is Cassava Sciences Inc a good stock to buy?

The fair value guage provides a quick view whether SAVA is over valued or under valued. Whether Cassava Sciences Inc is cheap or expensive depends on the assumptions which impact Cassava Sciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SAVA.

What is Cassava Sciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, SAVA's PE ratio (Price to Earnings) is -1.41 and Price to Sales (PS) ratio is 56.88. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SAVA PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Cassava Sciences Inc's stock?

In the past 10 years, Cassava Sciences Inc has provided -0.136 (multiply by 100 for percentage) rate of return.